Patent
The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
1. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinolic acid (THCa).
2. The formulation of claim 1 , further comprising at least one terpene/flavonoid.
3. The formulation of claim 2 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
4. The formulation of claim 2 , wherein the formulation comprises no more than 4% terpene.
5. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinol (THC).
6. The formulation-of claim 5 , further comprising at least one terpene/flavonoid.
7. The formulation of claim 5 , wherein the formulation comprises no more than 4% terpene.
8. The formulation of claim 6 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
9. The formulation of claim 1 or 5 , wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.
10. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is cannabidiol (CBD).
11. The formulation of claim 10 , wherein the formulation further comprises less than 1% THC.
12. The formulation-of claim 10 , further comprising at least one terpene/flavonoid.
13. The formulation of claim 10 , wherein the formulation comprises no more than 4% terpene.
14. The formulation of claim 12 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
15. The formulation of claim 10 , wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.
16. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is THCa and cannabidiolic acid (CBDa).
17. The formulation-of claim 16 , further comprising at least one terpene/flavonoid.
18. The formulation of claim 16 , wherein the formulation comprises no more than 4% terpene.
19. The formulation of claim 17 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
20. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are THC and CBD.
21. The formulation-of claim 20 , further comprising at least one terpene/flavonoid.
22. The formulation of claim 20 , wherein the formulation comprises no more than 4% terpene.
23. The formulation of claim 21 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
24. The formulation of claim 16 or 20 , wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, limonene, pinene, and caryophyllene.
25. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are CBD, cannabinol (CBN) and THC.
26. The formulation of claim 25 , wherein the formulation comprises less than 9% THC.
27. The formulation-of claim 25 , further comprising at least one terpene/flavonoid.
28. The formulation of claim 25 , wherein the formulation comprises no more than 4% terpene.
29. The formulation of claim 27 , wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.
30. The formulation of claim 25 , wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, pinene and caryophyllene.
31. The formulation of any one of the proceeding claims, wherein the formulation is infused in a medium chain triglyceride (MCT).
32. The formulation of claim 31 , wherein the MCT is NEOBEE 895.
33. The formulation of claim 1 , 5 , 10 , 16 , 20 , or 25 , formulated for oral, sublingual, buccal, or topical administration.
34. The formulation of claim 33 , wherein the sublingual formulation further comprises a sweetener.
35. The formulation of claim 34 , wherein the sweetener is a stevia extract.
36. The formulation of claim 34 , further comprising lemon oil, orange oil or both.